Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
BenevolentAI and AstraZeneca Collaboration Yields Further Novel Target Progress
Details : AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI and by using its AI-drug discovery platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration
Details : Under the collaboration, Sygnature Discovery will provide its proprietary Fragment-Based Drug Discovery (FBDD) and virtual high throughput screening (vHTS) to accelerate discovery of Daewoong's novel small molecule to target autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Epidarex Capital
Deal Size : $11.8 million
Deal Type : Financing
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
Details : This financing will be used to build out its core team and to fund preclinical indication expansion studies as well as to initiate development of oral formulations of KMO inhibitors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 04, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Epidarex Capital
Deal Size : $11.8 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Quellis Biosciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration
IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics
Details : Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed target...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Quellis Biosciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Inotrem
Deal Size : Undisclosed
Deal Type : Collaboration
IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets with Inotrem
Details : As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Inotrem
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments
Details : GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities to discover and validate novel materials for the treatment of SLE and ther aut...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 26, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement